{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T16:10:44Z","timestamp":1793376644875,"version":"4.5.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T00:00:00Z","timestamp":1727481600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172578"],"award-info":[{"award-number":["82172578"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.breast.2024.103818","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T05:57:32Z","timestamp":1727675852000},"page":"103818","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Clinical significance of serum estradiol monitoring in women receiving adjuvant aromatase inhibitor for hormone receptor-positive early breast cancer"],"prefix":"10.1016","volume":"78","author":[{"given":"Shuqin","family":"Dai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingping","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7632-3648","authenticated-orcid":false,"given":"Jibin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shusen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanxia","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoming","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajia","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinhua","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rouxi","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiufan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuikui","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongyi","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongyu","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiwen","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.breast.2024.103818_bib1","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju055","article-title":"US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status","volume":"106","author":"Howlader","year":"2014","journal-title":"J Natl Cancer Inst"},{"issue":"23","key":"10.1016\/j.breast.2024.103818_bib2","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1200\/JCO.2009.26.3756","article-title":"American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer","volume":"28","author":"Burstein","year":"2010","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.breast.2024.103818_bib3","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1200\/JCO.2015.65.9573","article-title":"Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American society of clinical oncology clinical practice guideline update on ovarian suppression","volume":"34","author":"Burstein","year":"2016","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.breast.2024.103818_bib4","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1200\/JCO.2009.26.5884","article-title":"Phase II parallel group study showing comparable efficacy between premenopausal metastatic breast cancer patients treated with letrozole plus goserelin and postmenopausal patients treated with letrozole alone as first-line hormone therapy","volume":"28","author":"Park","year":"2010","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.breast.2024.103818_bib5","doi-asserted-by":"crossref","first-page":"3917","DOI":"10.1200\/JCO.2009.24.9565","article-title":"Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women","volume":"28","author":"Carlson","year":"2010","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.breast.2024.103818_bib6","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1016\/j.ejca.2010.08.005","article-title":"Suppression of ovarian function in combination with an aromatase inhibitor as treatment for advanced breast cancer in pre-menopausal women","volume":"46","author":"Cheung","year":"2010","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.breast.2024.103818_bib7","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/sj.bjc.6603947","article-title":"Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer","volume":"97","author":"Torrisi","year":"2007","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.breast.2024.103818_bib8","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1001\/jamaoncol.2023.0089","article-title":"Efficacy of alternative dose regimens of exemestane in postmenopausal women with stage 0 to II estrogen receptor-positive breast cancer: a randomized clinical trial","volume":"9","author":"Serrano","year":"2023","journal-title":"JAMA Oncol"},{"issue":"5","key":"10.1016\/j.breast.2024.103818_bib9","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1200\/JCO.18.00296","article-title":"Neoadjuvant degarelix versus triptorelin in premenopausal patients who receive letrozole for locally advanced endocrine-responsive breast cancer: a randomized phase II trial","volume":"37","author":"Dellapasqua","year":"2019","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.breast.2024.103818_bib10","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1200\/JCO.2005.05.3694","article-title":"Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines","volume":"24","author":"Smith","year":"2006","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.breast.2024.103818_bib11","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.2015.61.2259","article-title":"Twelve-Month estrogen levels in premenopausal women with hormone receptor-positive breast cancer receiving adjuvant triptorelin plus exemestane or tamoxifen in the suppression of ovarian function trial (SOFT): the SOFT-EST substudy","volume":"34","author":"Bellet","year":"2016","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.breast.2024.103818_bib12","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djx074","article-title":"Ovarian function recovery during anastrozole in breast cancer patients with chemotherapy-induced ovarian function failure","volume":"109","author":"van Hellemond","year":"2017","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.breast.2024.103818_bib13","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1093\/annonc\/mds464","article-title":"Incidence and predictors of ovarian function recovery (OFR) in breast cancer (BC) patients with chemotherapy-induced amenorrhea (CIA) who switched from tamoxifen to exemestane","volume":"24","author":"Guerrero","year":"2013","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.breast.2024.103818_bib14","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1093\/annonc\/mdt149","article-title":"Predictors of recovery of ovarian function during aromatase inhibitor therapy","volume":"24","author":"Henry","year":"2013","journal-title":"Ann Oncol"},{"issue":"14","key":"10.1016\/j.breast.2024.103818_bib15","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1200\/JCO.2015.62.2985","article-title":"Incidence and predictive factors for recovery of ovarian function in amenorrheic women in their 40s treated with letrozole","volume":"34","author":"Krekow","year":"2016","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.breast.2024.103818_bib16","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.clbc.2022.09.007","article-title":"Measurable serum estradiol and estrone in women 36-56 Years during adjuvant treatment with aromatase inhibitors for a hormone receptor-positive breast cancer. Case studies and cross-sectional study using an ultra-sensitive LC-MS\/MS-Method","volume":"23","author":"Van Houdt","year":"2023","journal-title":"Clin Breast Cancer"},{"issue":"1","key":"10.1016\/j.breast.2024.103818_bib17","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/ijc.32093","article-title":"Efficacy of anastrozole after tamoxifen in early breast cancer patients with chemotherapy-induced ovarian function failure","volume":"145","author":"van Hellemond","year":"2019","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.breast.2024.103818_bib18","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s12032-012-0354-1","article-title":"Two different formulations with equivalent effect? Comparison of serum estradiol suppression with monthly goserelin and trimonthly leuprolide in breast cancer patients","volume":"30","author":"Aydiner","year":"2013","journal-title":"Med Oncol"},{"issue":"2","key":"10.1016\/j.breast.2024.103818_bib19","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s10549-010-1332-y","article-title":"Monthly versus 3-monthly goserelin acetate treatment in pre-menopausal patients with estrogen receptor-positive early breast cancer","volume":"126","author":"Masuda","year":"2011","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.breast.2024.103818_bib20","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s12282-016-0691-6","volume":"24","author":"Kurebayashi","year":"2017","journal-title":"Breast Cancer"},{"issue":"14","key":"10.1016\/j.breast.2024.103818_bib21","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1200\/JCO.2015.62.3728","article-title":"Incomplete estrogen suppression with gonadotropin-releasing hormone agonists may reduce clinical efficacy in premenopausal women with early breast cancer","volume":"34","author":"Dowsett","year":"2016","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.breast.2024.103818_bib22","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3322\/caac.21415","article-title":"Risk of ovarian function recovery should be considered when switching from treatment with adjuvant tamoxifen to aromatase inhibitor therapy in women with chemotherapy-induced amenorrhea","volume":"68","author":"Chung","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"14","key":"10.1016\/j.breast.2024.103818_bib23","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1200\/JCO.2015.65.3493","article-title":"Is estradiol monitoring necessary in women receiving ovarian suppression for breast cancer?","volume":"34","author":"Papakonstantinou","year":"2016","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.breast.2024.103818_bib24","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1200\/JCO.2013.53.9411","article-title":"Interpreting plasma estrogen levels in breast cancer: caution needed","volume":"32","author":"Folkerd","year":"2014","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.breast.2024.103818_bib25","first-page":"1101","article-title":"Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study","volume":"3","author":"Johannessen","year":"1997","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.breast.2024.103818_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0148849","article-title":"Ovarian function, not age, predicts the benefit from ovarian suppression or ablation for premenopausal women with breast cancer","volume":"11","author":"Xue","year":"2016","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.breast.2024.103818_bib27","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s10549-018-4997-2","article-title":"Pretreatment anti-Mullerian hormone-based nomogram predicts menstruation status after chemotherapy for premenopausal women with hormone receptor-positive early breast cancer","volume":"173","author":"Xue","year":"2019","journal-title":"Breast Cancer Res Treat"},{"issue":"Pt A","key":"10.1016\/j.breast.2024.103818_bib28","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.steroids.2014.08.007","article-title":"Estrogens and their precursors in postmenopausal women with early breast cancer receiving anastrozole","volume":"99","author":"Ingle","year":"2015","journal-title":"Steroids"},{"issue":"1","key":"10.1016\/j.breast.2024.103818_bib29","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41523-024-00614-w","article-title":"Selection of appropriate biomarkers to monitor effectiveness of ovarian function suppression in pre-menopausal patients with ER+ breast cancer","volume":"10","author":"McCann","year":"2024","journal-title":"NPJ Breast Cancer"},{"issue":"12","key":"10.1016\/j.breast.2024.103818_bib30","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1093\/jnci\/djab111","article-title":"Assessment of ovarian function in phase III (Neo)Adjuvant breast cancer clinical trials: a systematic evaluation","volume":"113","author":"Cui","year":"2021","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"10.1016\/j.breast.2024.103818_bib31","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1001\/jamaoncol.2019.0620","article-title":"Insights into breast cancer in the east vs the west: a review","volume":"5","author":"Yap","year":"2019","journal-title":"JAMA Oncol"},{"issue":"9","key":"10.1016\/j.breast.2024.103818_bib32","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s11427-019-1625-1","article-title":"Introduction of a multicenter online database for non-metastatic breast cancer in China","volume":"63","author":"Yang","year":"2020","journal-title":"Sci China Life Sci"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977624001498?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977624001498?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T23:58:54Z","timestamp":1733183934000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977624001498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":32,"alternative-id":["S0960977624001498"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2024.103818","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical significance of serum estradiol monitoring in women receiving adjuvant aromatase inhibitor for hormone receptor-positive early breast cancer","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2024.103818","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103818"}}